List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3383810/publications.pdf Version: 2024-02-01



Δηρφείλι Τ.Υλη

#	Article	IF	CITATIONS
1	Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Post–Myocardial Infarction Mortality. Circulation, 2006, 114, 32-39.	1.6	732
2	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371
3	Tissue Expression and Immunolocalization of Tumor Necrosis Factor-α in Postinfarction Dysfunctional Myocardium. Circulation, 1999, 99, 1492-1498.	1.6	353
4	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. European Heart Journal, 2007, 28, 1072-1078.	2.2	226
5	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2020, 141, 704-707.	1.6	225
6	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
7	Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?. Diabetes Care, 2016, 39, e212-e213.	8.6	190
8	Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. American Heart Journal, 2012, 163, 66-73.	2.7	168
9	Factors influencing underutilization of evidence-based therapies in women. European Heart Journal, 2011, 32, 1337-1344.	2.2	166
10	The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. American Heart Journal, 2009, 158, 193-201.e5.	2.7	165
11	Association Between Cardiovascular RiskÂFactors and Aortic Stenosis. Journal of the American College of Cardiology, 2017, 69, 1523-1532.	2.8	162
12	Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. American Heart Journal, 2009, 158, 392-399.	2.7	160
13	Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. American Journal of Medicine, 2006, 119, 676-683.	1.5	148
14	Management Patterns in Relation to Risk Stratification Among Patients With Non–ST Elevation Acute Coronary Syndromes. Archives of Internal Medicine, 2007, 167, 1009.	3.8	147
15	Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome. American Heart Journal, 2007, 154, 1108-1115.	2.7	141
16	Understanding Physicians' Risk Stratification of Acute Coronary Syndromes. Archives of Internal Medicine, 2009, 169, 372.	3.8	114
17	In-Hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. American Journal of Cardiology, 2005, 96, 913-916.	1.6	108
18	Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management. Canadian Journal of Cardiology, 2014, 30, 869-878.	1.7	105

#	Article	IF	CITATIONS
19	Age-related differences in the management and outcome of patients with acute coronary syndromes. American Heart Journal, 2006, 151, 352-359.	2.7	94
20	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non–ST elevation acute coronary syndromes. American Heart Journal, 2007, 154, 71-78.	2.7	93
21	One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary) Tj ETQq1	1 0.784314 1.6	rgBT /Overlo
22	Clinical trial–derived risk model may not generalize to real-world patients with acute coronary syndrome. American Heart Journal, 2004, 148, 1020-1027.	2.7	84
23	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. European Heart Journal, 2009, 30, 549-557.	2.2	84
24	Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. Journal of the American Society of Nephrology: JASN, 2019, 30, 641-652.	6.1	83
25	Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. PLoS Medicine, 2018, 15, e1002501.	8.4	82
26	Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non–ST-Elevation Myocardial Infarction, 2003-2013. JAMA - Journal of the American Medical Association, 2016, 316, 1073.	7.4	80
27	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metabolism, 2019, 30, 609-613.	16.2	69
28	Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both. American Journal of Cardiology, 2005, 96, 698-704.	1.6	67
29	Plasma Matrix Metalloproteinase-9 Level Is Correlated With Left Ventricular Volumes and Ejection Fraction in Patients With Heart Failure. Journal of Cardiac Failure, 2006, 12, 514-519.	1.7	67
30	Influence of Age on Use of Cardiac Catheterization and Associated Outcomes in Patients With Non-ST-Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2009, 103, 1530-1536.	1.6	67
31	The Role of Continuous Positive Airway Pressure in the Treatment of Congestive Heart Failure. Chest, 2001, 120, 1675-1685.	0.8	66
32	Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. European Heart Journal, 2010, 31, 875-882.	2.2	66
33	Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. International Journal of Cardiology, 2018, 261, 228-233.	1.7	65
34	Applying the Evidence. Stroke, 2009, 40, 1417-1424.	2.0	64
35	Optimal Medical Therapy for Non–ST-Segment–Elevation Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 530-537	2.2	64
36	Use of Cardiac Catheterization for Non–ST-Segment Elevation Acute Coronary Syndromes According to Initial Risk <subtitle>Reasons Why Physicians Choose Not to Refer Their Patients</subtitle> . Archives of Internal Medicine, 2008, 168, 291.	3.8	63

#	Article	IF	CITATIONS
37	The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute, 2016, 108, djv301.	6.3	62
38	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. European Heart Journal, 2018, 39, 3798-3806.	2.2	62
39	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. European Heart Journal, 2015, 36, 976-983.	2.2	61
40	Characterization of Microvascular Dysfunction After Acute Myocardial Infarction by Cardiovascular Magnetic Resonance First-Pass Perfusion and Late Gadolinium Enhancement Imaging. Journal of Cardiovascular Magnetic Resonance, 2006, 8, 831-837.	3.3	60
41	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. Journal of the American Heart Association, 2018, 7, e009859.	3.7	60
42	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2017, 33, 737-746.	1.7	58
43	Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials. Canadian Journal of Cardiology, 2019, 35, 653-660.	1.7	56
44	Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization. Journal of the American Heart Association, 2017, 6, .	3.7	52
45	Empagliflozin Reduces Myocardial Extracellular Volume in Patients WithÂType 2 Diabetes and CoronaryÂArtery Disease. JACC: Cardiovascular Imaging, 2021, 14, 1164-1173.	5.3	51
46	Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer. JACC: Cardiovascular Imaging, 2021, 14, 962-974.	5.3	50
47	Canada Acute Coronary Syndrome Risk Score: A new risk score for early prognostication in acute coronary syndromes. American Heart Journal, 2013, 166, 58-63.	2.7	49
48	Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 44.	3.3	46
49	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. American Heart Journal, 2006, 152, 676-683.	2.7	43
50	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. Circulation, 2015, 132, 2345-2350.	1.6	42
51	Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. Annals of Internal Medicine, 2005, 142, 132.	3.9	40
52	Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 166-174.	2.9	39
53	The differential association between various anthropometric indices of obesity and subclinical atherosclerosis. Atherosclerosis, 2009, 207, 232-238.	0.8	38
54	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2015, 31, 1455-1461.	1.7	37

#	Article	IF	CITATIONS
55	Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers. Clinical Drug Investigation, 2018, 38, 341-351.	2.2	37
56	Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. Canadian Journal of Cardiology, 2006, 22, 115-120.	1.7	35
57	Comparison of Baseline Characteristics, Management and Outcome of Patients With Non–ST-Segment Elevation Acute Coronary Syndrome in Versus Not in Clinical Trials. American Journal of Cardiology, 2010, 106, 1389-1396.	1.6	35
58	Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. European Journal of Heart Failure, 2008, 10, 125-128.	7.1	34
59	Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients. American Journal of Cardiology, 2010, 106, 1270-1276.	1.6	34
60	Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). European Heart Journal, 2011, 32, 1994-2002.	2.2	34
61	Relation Between Hemoglobin Level and Recurrent Myocardial Ischemia in Acute Coronary Syndromes Detected by Continuous Electrocardiographic Monitoring. American Journal of Cardiology, 2010, 106, 1417-1422.	1.6	33
62	Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. Canadian Journal of Cardiology, 2009, 25, e370-e376.	1.7	32
63	Prognostic value of visually detected coronary artery calcification on unenhanced non-gated thoracic computed tomography for prediction of non-fatal myocardial infarction and all-cause mortality. Journal of Cardiovascular Computed Tomography, 2017, 11, 196-202.	1.3	32
64	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 350-358.	1.0	31
65	Myocardial Fibroma in Gorlin Syndrome by Cardiac Magnetic Resonance Imaging. Circulation, 2006, 114, e376-9.	1.6	30
66	Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 69.	3.3	30
67	Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrology, 2012, 13, 3.	1.8	30
68	Thiamin deficiency and heart failure: the current knowledge and gaps in literature. Heart Failure Reviews, 2015, 20, 1-11.	3.9	29
69	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes. JAMA Cardiology, 2021, 6, 304.	6.1	29
70	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrology Dialysis Transplantation, 2019, 34, 339-346.	0.7	28
71	Disparities in Management Patterns and Outcomes of Patients With Non–ST-Elevation Acute Coronary Syndrome With and Without a History of Cerebrovascular Disease. American Journal of Cardiology, 2010, 105, 1083-1089.	1.6	27
72	The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease. Canadian Journal of Cardiology, 2016, 32, 369-377.	1.7	27

#	Article	IF	CITATIONS
73	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. BMJ Open, 2019, 9, e032165.	1.9	27
74	ST-segment depression in non–ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. American Heart Journal, 2006, 152, 270-276.	2.7	26
75	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. Canadian Journal of Cardiology, 2014, 30, 1725-1731.	1.7	26
76	Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. European Heart Journal, 2004, 25, 2006-2012.	2.2	25
77	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Canadian Journal of Cardiology, 2007, 23, 1124-1130.	1.7	25
78	Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for non–ST-elevation acute coronary syndromes. American Heart Journal, 2011, 162, 347-355.e1.	2.7	25
79	Comparative Assessment of 2-Dimensional Echocardiography vs Cardiac Magnetic Resonance Imaging in Measuring Left Ventricular Mass in Patients With and Without End-Stage Renal Disease. Canadian Journal of Cardiology, 2013, 29, 384-390.	1.7	25
80	Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 965-973.	4.5	25
81	Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 436-444.	4.5	25
82	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Canadian Journal of Diabetes, 2018, 42, 130-137.	0.8	25
83	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e42-e44.	8.6	25
84	Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. American Heart Journal, 2010, 159, 40-46.	2.7	24
85	Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). American Heart Journal, 2010, 160, 479-486.	2.7	24
86	Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 83.	3.3	24
87	Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. International Journal of Cardiovascular Imaging, 2019, 35, 653-662.	1.5	24
88	Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. Nephrology Dialysis Transplantation, 2012, 27, 1591-1598.	0.7	23
89	Treatment and Outcomes of Patients With Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions (Insights from the Canadian Global Registry of Acute Coronary Events [GRACE]) Tj ETQq1 202-207	1,0,7843 1.6	14 rgBT /Ov
90	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). American Heart Journal, 2015, 170, 995-1004.e1.	2.7	23

#	Article	IF	CITATIONS
91	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Research and Treatment, 2016, 157, 535-544.	2.5	23
92	Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. American Heart Journal, 2007, 153, 500-506.	2.7	22
93	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. American Heart Journal, 2010, 160, 420-427.	2.7	22
94	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. American Heart Journal, 2010, 160, 855-861.	2.7	22
95	The Role of B Vitamins in the Management of Heart Failure. Nutrition in Clinical Practice, 2012, 27, 363-374.	2.4	22
96	Prognostic significance of presenting blood pressure in non–ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. American Heart Journal, 2013, 166, 716-722.	2.7	22
97	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.7	22
98	QRS prolongation in patients with acute coronary syndromes. American Heart Journal, 2010, 159, 593-598.	2.7	20
99	Management and Outcome of Acute Coronary Syndrome Patients in Relation to Prior History of Atrial Fibrillation. Canadian Journal of Cardiology, 2012, 28, 443-449.	1.7	20
100	Use and Timing of Coronary Angiography and Associated In-hospital Outcomes in Canadian Non–ST-Segment Elevation Myocardial Infarction Patients: Insights from the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2013, 29, 1429-1435.	1.7	20
101	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2013, 166, 290-297.	2.7	20
102	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. International Journal of Cardiology, 2015, 190, 34-39.	1.7	20
103	Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. Cancer, 2018, 124, 1269-1278.	4.1	20
104	Peri-Infarct Quantification by Cardiac Magnetic Resonance to Predict Outcomes in Ischemic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2019, 12, e009156.	2.6	20
105	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. American Heart Journal, 2016, 180, 82-89.	2.7	19
106	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. International Journal of Cardiology, 2017, 244, 24-29.	1.7	19
107	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	8.6	19
108	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. American Heart Journal, 2009, 158, 917-924.	2.7	18

#	Article	IF	CITATIONS
109	Correlates of left ventricular mass in chronic hemodialysis recipients. International Journal of Cardiovascular Imaging, 2014, 30, 349-356.	1.5	18
110	Patient characteristics associated with self-presentation, treatment delay and survival following primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 214-222.	1.0	18
111	Trends in the incidence and outcomes of patients with aortic stenosis hospitalization. American Heart Journal, 2018, 199, 144-149.	2.7	18
112	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Journal of the American Society of Echocardiography, 2020, 33, 644-646.	2.8	18
113	Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes and Their Relation to Outcome. American Journal of Cardiology, 2007, 100, 169-174.	1.6	17
114	Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. American Heart Journal, 2008, 156, 769-775.	2.7	17
115	Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study. International Journal of Cardiovascular Imaging, 2019, 35, 2085-2093.	1.5	17
116	Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world―setting. Medical Oncology, 2017, 34, 154.	2.5	16
117	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. American Journal of Cardiology, 2016, 117, 754-759.	1.6	15
118	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. International Journal of Cardiology, 2017, 240, 30-36.	1.7	15
119	Reperfusion Strategies and Outcomes of ST-Segment Elevation Myocardial Infarction Patients in Canada: Observations From the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). Canadian Journal of Cardiology, 2012, 28, 40-47.	1.7	14
120	Relationship between different blood pressure measurements and left ventricular mass by cardiac magnetic resonance imaging in end–stage renal disease. Journal of the American Society of Hypertension, 2015, 9, 275-284.	2.3	14
121	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 277-284.	4.0	14
122	Left ventricular structure and diastolic function by cardiac magnetic resonance imaging in hypertrophic cardiomyopathy. Indian Heart Journal, 2018, 70, 75-81.	0.5	14
123	Excessive exercise in endurance athletes: Is atrial fibrillation a possible consequence?. Applied Physiology, Nutrition and Metabolism, 2018, 43, 973-976.	1.9	14
124	Thiamin supplementation does not improve left ventricular ejection fraction in ambulatory heart failure patients: a randomized controlled trial. American Journal of Clinical Nutrition, 2019, 110, 1287-1295.	4.7	14
125	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabolism Open, 2020, 7, 100039.	2.9	14
126	Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. Breast Cancer Research and Treatment, 2020, 181, 155-165.	2.5	14

#	Article	IF	CITATIONS
127	Recurrent ischemia across the spectrum of acute coronary syndromes: Prevalence and prognostic significance of (Re-)infarction and ST-segment changes in a large contemporary registry. International Journal of Cardiology, 2010, 145, 15-20.	1.7	13

128 Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the) Tj ETQq0 0 0 rgBT /Overlock 10 T

129	Assessment of right ventricular volumes and function using cardiovascular magnetic resonance cine imaging after atrial redirection surgery for complete transposition of the great arteries. International Journal of Cardiovascular Imaging, 2013, 29, 335-342.	1.5	13
130	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart, 2016, 102, 1396-1402.	2.9	13
131	Determinants of Left Ventricular Characteristics Assessed by Cardiac Magnetic Resonance Imaging and Cardiovascular Biomarkers Related to Kidney Transplantation. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811880997.	1.1	13
132	Growth differentiation factor 15 is decreased by kidney transplantation. Clinical Biochemistry, 2019, 73, 57-61.	1.9	13
133	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006646.	2.2	13
134	Population-Based Study on Patterns of Cardiac Stress Testing After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	12
135	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 309-317.	4.0	12
136	Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. European Heart Journal, 2007, 29, 31-37.	2.2	11
137	Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. American Journal of Cardiology, 2008, 101, 919-924.	1.6	11
138	Evaluation of left ventricular ejection fraction in non–ST-segment elevation acute coronary syndromes and its relationship to treatment. American Heart Journal, 2010, 159, 605-611.	2.7	11
139	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Canadian Journal of Cardiology, 2011, 27, 711-715.	1.7	11
140	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 214-222.	1.0	11
141	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2018, 122, 944-951.	1.6	11
142	The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1470-1479.	4.5	11
143	Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets. Diabetes Care, 2010, 33, 2558-2560.	8.6	10
144	Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2010, 31, 958-966.	2.2	10

ANDREW T YAN

#	Article	IF	CITATIONS
145	Temporal Trends and Referral Factors for Cardiac Rehabilitation Post-Acute Coronary Syndrome in Ontario: Insights From the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2013, 29, 1604-1609.	1.7	10
146	Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 31-36.	4.0	10
147	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. Heart, 2015, 101, 1554-1561.	2.9	10
148	Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open, 2016, 4, E66-E72.	2.4	10
149	Relationships Between Left Ventricular Structure and Function According to Cardiac MRI and Cardiac Biomarkers in End-Stage Renal Disease. Canadian Journal of Cardiology, 2017, 33, 501-507.	1.7	10
150	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Canadian Journal of Cardiology, 2018, 34, 736-743.	1.7	10
151	Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab. American Journal of Cardiology, 2019, 123, 1173-1179.	1.6	10
152	Left Ventricular Fibrosis in Middle-Age Athletes and Physically Active Adults. Medicine and Science in Sports and Exercise, 2020, 52, 2500-2507.	0.4	10
153	Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 200.	6.8	10
154	Impact of delayed presentation on management and outcome of non–ST-elevation acute coronary syndromes. American Heart Journal, 2008, 156, 262-268.	2.7	9
155	The Association Between Prior Use of Aspirin and/or Warfarin and the In-hospital Management and Outcomes in Patients Presenting With Acute Coronary Syndromes: Insights From the Global Registry of Acute Coronary Events (GRACE). Canadian Journal of Cardiology, 2012, 28, 48-53.	1.7	9
156	Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After) Tj ETQq0 0 2014, 114, 955, 961	0 rgBT /O	verjock 10 Tf
157	Reduction of carbamylated albumin by extended hemodialysis. Hemodialysis International, 2016, 20, 510-521.	0.9	9
158	Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	9
159	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. CJC Open, 2020, 2, 118-128.	1.5	9
160	Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes. American Heart Journal, 2008, 156, 797-803.	2.7	8
161	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non–ST-elevation acute coronary syndromes. American Heart Journal, 2011, 161, 878-885.	2.7	8
162	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. International Journal of Cardiology, 2016, 218, 291-297.	1.7	8

#	Article	IF	CITATIONS
163	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 582-587.	1.6	8
164	Association between conversion to in-center nocturnal hemodialysis and right ventricular remodeling. Nephrology Dialysis Transplantation, 2018, 33, 1010-1016.	0.7	8
165	The management of left ventricular systolic dysfunction in patients with advanced chronic kidney disease. Journal of Nephrology, 2011, 24, 41-49.	2.0	8
166	Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2008, 155, 718-724.	2.7	7
167	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). American Heart Journal 2012, 164, 343-350	2.7	7
168	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. Canadian Journal of Cardiology, 2016, 32, 1221.e11-1221.e18.	1.7	7
169	Relationship between changes in blood pressure and left ventricular mass over 1 year in end-stage renal disease. Journal of Hypertension, 2017, 35, 1709-1716.	0.5	7
170	A Randomized Control Trial Using a Validated Prediction Model for Diagnosing Acute Heart Failure in Undifferentiated Dyspneic Emergency Department Patients—Results of the GASP4Ar Study. Journal of Cardiac Failure, 2017, 23, 145-152.	1.7	7
171	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). Clinical Cardiology, 2018, 41, 285-292.	1.8	7
172	Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. Heart, 2019, 105, 1649-1655.	2.9	7
173	Cardiac Remodeling in Middle-Aged Endurance Athletes and Recreationally Active Individuals: Challenges in Defining the "Athlete's Heart― Journal of the American Society of Echocardiography, 2020, 33, 247-249.	2.8	7
174	Low-molecular-weight heparins in ischemic heart disease. Current Opinion in Cardiology, 2004, 19, 309-316.	1.8	6
175	Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. CKJ: Clinical Kidney Journal, 2012, 5, 124-129.	2.9	6
176	Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. American Heart Journal, 2014, 168, 757-765.e3.	2.7	6
177	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. American Journal of Cardiology, 2018, 121, 294-300.	1.6	6
178	Immediate non-culprit vessel percutaneous coronary intervention (PCI) in patients with acute myocardial infarction and cardiogenic shock: a swinging pendulum. Journal of Thoracic Disease, 2018, 10, 661-666.	1.4	6
179	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 309-317.	1.0	6
180	Development of Acute Myocardial Infarction Mortality and Readmission Models for Public Reporting on Hospital Performance in Canada. CJC Open, 2021, 3, 1051-1059.	1.5	6

ANDREW T YAN

1.1

4

#	Article	IF	CITATIONS
181	Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2011, 161, 291-297.	2.7	5
182	Management of Risk Factors Among Ambulatory Patients at High Cardiovascular Risk in Canada: A Follow-up Study. Canadian Journal of Cardiology, 2013, 29, 1586-1592.	1.7	5
183	Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. International Journal of Cardiology, 2013, 168, 2720-2725.	1.7	5
184	Efficacy of an Early Invasive Strategy After Fibrinolysis in ST-Elevation Myocardial Infarction Relative to the Extent of Coronary Artery Disease. Canadian Journal of Cardiology, 2014, 30, 1555-1561.	1.7	5
185	Cardiac magnetic resonance imaging for non-invasive diagnosis of lipomatous hypertrophy of inter-atrial septum. Indian Heart Journal, 2014, 66, 244-246.	0.5	5
186	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. European Heart Journal Quality of Care & amp; Clinical Outcomes, 2016. 3. ocw051.	4.0	5
187	Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials. Cardiovascular Revascularization Medicine, 2016, 17, 295-301.	0.8	5
188	Left ventricular strain analysis using cardiac magnetic resonance imaging in patients undergoing inâ€centre nocturnal haemodialysis. Nephrology, 2019, 24, 557-563.	1.6	5
189	Clinical application of echocardiographic-derived myocardial strain imaging in subclinical disease. Current Opinion in Cardiology, 2019, 34, 147-155.	1.8	5
190	Left Atrial Remodeling Assessed by Cardiac MRI after Conversion from Conventional HemodialysisÂto In-Centre Nocturnal Hemodialysis. Journal of Nephrology, 2019, 32, 273-281.	2.0	5
191	Sex-Specific Differences in New York Heart Association Classification and Outcomes of Decompensated Heart Failure. Canadian Journal of Cardiology, 2020, 36, 4-6.	1.7	5
192	Cardiac MRI measurements of pericardial adipose tissue volumes in patients on in-centre nocturnal hemodialysis. Journal of Nephrology, 2020, 33, 355-363.	2.0	5
193	From Mars to Venus: Gender Differences in the Management and Outcomes of Acute Coronary Syndromes. Current Pharmaceutical Design, 2016, 22, 3790-3801.	1.9	5
194	Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis. Heart Asia, 2012, 4, 137-140.	1.1	4
195	Relation Between Previous Angiotensin-Converting Enzyme Inhibitor Use and In-Hospital Outcomes in Acute Coronary Syndromes. American Journal of Cardiology, 2012, 109, 332-336.	1.6	4
196	Management and Outcomes of Non-ST Elevation Acute Coronary Syndromes in Relation to Previous Use of Antianginal Therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE]) Tj ETQq0 C 112, 51-56.) 0 rgBT /O	verlock 10 Tf
197	In enter Nocturnal Hemodialysis. Seminars in Dialysis, 2014, 27, 179-187.	1.3	4

Early Outgrowth Pro-Angiogenic Cell Number and Function Do Not Correlate with Left Ventricular Structure and Function in Conventional Hemodialysis Patients: A Cross-Sectional Study. Canadian Journal of Kidney Health and Disease, 2015, 2, 60.

#	Article	IF	CITATIONS
199	Reply. Journal of the American College of Cardiology, 2017, 70, 1104.	2.8	4
200	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes. Coronary Artery Disease, 2018, 29, 469-476.	0.7	4
201	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. Canadian Journal of Cardiology, 2019, 35, 160-168.	1.7	4
202	Stress cardiac MRI in stable coronary artery disease. Current Opinion in Cardiology, 2020, 35, 566-573.	1.8	4
203	Right Ventricular Function at Cardiac MRI Predicts Cardiovascular Events in Patients with an Implantable Cardioverter-Defibrillator. Radiology, 2021, 301, 322-329.	7.3	4
204	Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. Acta Diabetologica, 2022, 59, 575.	2.5	4
205	Cardiac magnetic resonance imaging of a large prolapsing left atrial myxoma causing pulmonary hypertension and syncope. Canadian Journal of Cardiology, 2010, 26, e134-e135.	1.7	3
206	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. Heart, 2014, 100, 1456-1461.	2.9	3
207	Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (a Subgroup Analysis of TRANSFER-AMI). American Journal of Cardiology, 2015, 115, 1005-1012.	1.6	3
208	The relationship between the proportion of admitted high risk ACS patients and hospital delivery of evidence based care. International Journal of Cardiology, 2016, 222, 86-92.	1.7	3
209	Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction. Journal of Arrhythmia, 2017, 33, 134-138.	1.2	3
210	Nutritional status after conversion from conventional to in-centre nocturnal hemodialysis. International Urology and Nephrology, 2017, 49, 1453-1461.	1.4	3
211	Cardiac MRI and radionuclide ventriculography for measurement of left ventricular ejection fraction in ICD candidates. Magnetic Resonance Imaging, 2018, 52, 69-74.	1.8	3
212	Prevalence of Thiamin Deficiency in Ambulatory Patients with Heart Failure. Journal of the Academy of Nutrition and Dietetics, 2019, 119, 1160-1167.	0.8	3
213	Global lessons for quality care: a tale of two countries. Heart, 2019, 105, 812-813.	2.9	3
214	Evaluation of left atrial remodeling in kidney transplant patients using cardiac magnetic resonance imaging. Journal of Nephrology, 2021, 34, 851-859.	2.0	3
215	Cardiac MRI assessment of the right ventricle pre-and post-kidney transplant. International Journal of Cardiovascular Imaging, 2021, 37, 1757-1766.	1.5	3
216	Contemporary use of guidelineâ€based higher potency P2Y12 receptor inhibitor therapy in patients with moderateâ€toâ€high risk nonâ€STâ€segment elevation myocardial infarction: Results from the Canadian ACS reflective II crossâ€sectional study. Clinical Cardiology, 2021, 44, 839-847.	1.8	3

#	Article	IF	CITATIONS
217	Awareness of Warning Symptoms of Heart Disease and Stroke: Results of a Follow-up Study of the Chinese Canadian Cardiovascular Health Project. CJC Open, 2021, 3, 741-750.	1.5	3
218	Prognostic value of cardiovascular magnetic resonance left ventricular volumetry and geometry in patients receiving an implantable cardioverter defibrillator. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 72.	3.3	3
219	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Heart and Vessels, 2022, 37, 1291-1298.	1.2	3
220	Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab. European Radiology, 2022, 32, 4234-4242.	4.5	3
221	Persistent Left Superior Vena Cava With Retrograde Drainage From the Left Atrium Into the Left Brachiocephalic Vein. Journal of the American College of Cardiology, 2011, 58, 2141.	2.8	2
222	Benign Intramyocardial Mesothelial Cyst in the Right Ventricular Outflow Tract. Circulation, 2014, 130, e275-7.	1.6	2
223	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. International Journal of Cardiology, 2015, 201, 493.	1.7	2
224	Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. American Heart Journal, 2017, 193, 46-54.	2.7	2
225	Reply to Sepehrvand etÂal.—Promoting Enrollment of Women in Cardiovascular Clinical Trials. Canadian Journal of Cardiology, 2020, 36, 969.e9.	1.7	2
226	Left atrial volume and function measured by cardiac magnetic resonance imaging as predictors of shocks and mortality in patients with implantable cardioverter-defibrillators. International Journal of Cardiovascular Imaging, 2021, 37, 2259-2267.	1.5	2
227	Clinical risk prediction models for the prognosis and management of acute coronary syndromes. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 222-228.	4.0	2
228	Atrial structure and function in middleâ€aged, physicallyâ€active males and females: A cardiac magnetic resonance study. Clinical Cardiology, 2021, 44, 1467-1474.	1.8	2
229	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. Journal of Diabetes and Its Complications, 2021, 35, 107997.	2.3	2
230	The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF). Acta Diabetologica, 2021, 58, 633-641.	2.5	2
231	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. Journal of Cardiology, 2021, , .	1.9	2
232	The Increase in Paraoxonase 1 Is Associated With Decrease in Left Ventricular Volume in Kidney Transplant Recipients. Frontiers in Cardiovascular Medicine, 2021, 8, 763389.	2.4	2
233	A new risk stratification tool for women with acute coronary syndrome. International Journal of Cardiology, 2018, 259, 53-54.	1.7	1
234	Cardiac remodeling in middle-aged endurance athletes: relation between signal-averaged electrocardiogram and LV mass. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H316-H322.	3.2	1

#	Article	IF	CITATIONS
235	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Canadian Journal of Diabetes, 2021, , .	0.8	1
236	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. CJC Open, 2021, 3, 1419-1427.	1.5	1
237	A Novel Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Biomarker Anti-DSG2 is Absent in Athletes with Right Ventricular Enlargement. CJC Open, 2021, 3, 1413-1418.	1.5	1
238	Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study. CJC Open, 2021, 3, 1463-1470.	1.5	1
239	Objective risk assessment vs standard care for acute coronary syndromes—The Australian GRACE Risk tool Implementation Study (AGRIS): a process evaluation. BMC Health Services Research, 2022, 22, 380.	2.2	1
240	AB50-5. Heart Rhythm, 2006, 3, S105.	0.7	0
241	Are acute coronary syndromes risk models too complex? reply. European Heart Journal, 2007, 28, 2176-2177.	2.2	Ο
242	Focal caseous mitral annular calfication: Evaluation with cardiac MRI. European Journal of Radiology Extra, 2010, 73, e53-e55.	0.1	0
243	Prognostic Implications of Prominent R Wave in Electrocardiographic Leads V1 or V2 in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2014, 113, 1962-1967.	1.6	Ο
244	Bridged Bilateral Superior Venae Cavae With Direct Left Atrial Appendage Connection and No Other Congenital Cardiac Anomaly. Canadian Journal of Cardiology, 2017, 33, 1066.e13-1066.e15.	1.7	0
245	Mineralocorticoid receptor antagonists for heart failure: lost in translation?. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 237-238.	4.0	0
246	CMR and Tissue Characterization. Journal of the American College of Cardiology, 2019, 73, 3359.	2.8	0
247	Predicting Sudden Death in Dilated Cardiomyopathy: The Potential Power of Magnetic Resonance Imaging as a Critical Tool. Canadian Journal of Cardiology, 2020, 36, 1006-1008.	1.7	Ο
248	Relationships between cardiac structural and functional assessment by cardiac MRI and hemoglobin in end-stage renal disease. Journal of Nephrology, 2021, 34, 1561-1563.	2.0	0
249	Exaggerated Blood Pressure Responses To Exercise: Assessment Of Criteria In Middle-aged Male Endurance Athletes. Medicine and Science in Sports and Exercise, 2021, 53, 9-10.	0.4	Ο
250	Looking beyond cancer for cabozantinib-induced cardiotoxicity: evidence of absence or absence of evidence?. Annals of Translational Medicine, 2019, 7, S121-S121.	1.7	0
251	Right Ventricular Mass 12 Years after Osteosarcoma: Multimodality Imaging with Pathologic Correlation. Radiology: Cardiothoracic Imaging, 2021, 3, e210191.	2.5	0
252	Mapping the burden of atherosclerosis: global lessons from Portugal. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 117-118.	4.0	0

#	Article	IF	CITATIONS
253	Myocardial strain assessment using cardiovascular magnetic resonance imaging in recipients of implantable cardioverter defibrillators. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 115.	3.3	0
254	Assessments of right ventricular strain using cardiac m <scp>agnetic resonance imaging</scp> following kidney transplantation. Nephrology, 2022, 27, 371-375.	1.6	0